{
  "thread": {
    "uuid": "ecf109e68a0cf4df286208ff8611ada9333e52bb",
    "url": "https://simplywall.st/stocks/cn/pharmaceuticals-biotech/szse-300463/maccura-biotechnologyltd-shares/news/maccura-biotechnology-coltd-szse300463-could-be-riskier-than",
    "site_full": "simplywall.st",
    "site": "simplywall.st",
    "site_section": "https://news.google.com/search?q=be%20when%3A1h&hl=en-US&gl=US&ceid=US%3Aen",
    "site_categories": [
      "investing",
      "financial_news",
      "finance"
    ],
    "section_title": "Google News - Search",
    "title": "Maccura Biotechnology Co.Ltd (SZSE:300463) Could Be Riskier Than It Looks",
    "title_full": "Maccura Biotechnology Co.Ltd (SZSE:300463) Could Be Riskier Than It Looks",
    "published": "2025-02-21T01:08:00.000+02:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "US",
    "main_image": "https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276",
    "performance_score": 0,
    "domain_rank": 20263,
    "domain_rank_updated": "2025-02-17T23:00:00.000+02:00",
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "ecf109e68a0cf4df286208ff8611ada9333e52bb",
  "url": "https://simplywall.st/stocks/cn/pharmaceuticals-biotech/szse-300463/maccura-biotechnologyltd-shares/news/maccura-biotechnology-coltd-szse300463-could-be-riskier-than",
  "ord_in_thread": 0,
  "parent_url": null,
  "author": "Simply Wall St",
  "published": "2025-02-21T01:08:00.000+02:00",
  "title": "Maccura Biotechnology Co.Ltd (SZSE:300463) Could Be Riskier Than It Looks",
  "text": "China- /\nLife Sciences- /\n- SZSE:300463\nMaccura Biotechnology Co.Ltd (SZSE:300463) Could Be Riskier Than It Looks\nWhen close to half the companies in China have price-to-earnings ratios (or \"P/E's\") above 37x, you may consider Maccura Biotechnology Co.Ltd (SZSE:300463) as an attractive investment with its 24.8x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's limited.\nRecent times haven't been advantageous for Maccura BiotechnologyLtd as its earnings have been falling quicker than most other companies. The P/E is probably low because investors think this poor earnings performance isn't going to improve at all. If you still like the company, you'd want its earnings trajectory to turn around before making any decisions. If not, then existing shareholders will probably struggle to get excited about the future direction of the share price.\n Check out our latest analysis for Maccura BiotechnologyLtd\nfree report on Maccura BiotechnologyLtdwill help you uncover what's on the horizon.\nWhat Are Growth Metrics Telling Us About The Low P/E?\nThe only time you'd be truly comfortable seeing a P/E as low as Maccura BiotechnologyLtd's is when the company's growth is on track to lag the market.\nTaking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 13%. As a result, earnings from three years ago have also fallen 71% overall. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.\nTurning to the outlook, the next year should generate growth of 57% as estimated by the three analysts watching the company. With the market only predicted to deliver 37%, the company is positioned for a stronger earnings result.\nWith this information, we find it odd that Maccura BiotechnologyLtd is trading at a P/E lower than the market. Apparently some shareholders are doubtful of the forecasts and have been accepting significantly lower selling prices.\nThe Key Takeaway\nTypically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.\nWe've established that Maccura BiotechnologyLtd currently trades on a much lower than expected P/E since its forecast growth is higher than the wider market. When we see a strong earnings outlook with faster-than-market growth, we assume potential risks are what might be placing significant pressure on the P/E ratio. It appears many are indeed anticipating earnings instability, because these conditions should normally provide a boost to the share price.\nHaving said that, be aware Maccura BiotechnologyLtd is showing 1 warning sign in our investment analysis, you should know about.\nIf these risks are making you reconsider your opinion on Maccura BiotechnologyLtd, explore our interactive list of high quality stocks to get an idea of what else is out there.\nNew: Manage All Your Stock Portfolios in One Place\nWe've created the ultimate portfolio companion for stock investors, and it's free.\n• Connect an unlimited number of Portfolios and see your total in one currency\n• Be alerted to new Warning Signs or Risks via email or mobile\n• Track the Fair Value of your stocks\nTry a Demo Portfolio for Free\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\nThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\nAbout SZSE:300463\nMaccura BiotechnologyLtd\nEngages in the research, development, manufacture, and sale of IVD products and related services in China and internationally.\nFlawless balance sheet and undervalued.\nSimilar Companies\nMarket Insights\nCommunity Narratives\nFiverr aims for greater revenue with expansive enterprise solutions and AI\nSoundHound’s Moat And Diversified Revenue Strategy Make It A Voice AI Leader\nEquity Analyst and Writer\nMedtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "negative",
  "categories": [
    "Economy, Business and Finance",
    "Health",
    "Social Issue"
  ],
  "topics": [
    "Economy, Business and Finance->healthcare industry",
    "Health->health organisation",
    "Health->medical profession",
    "Social Issue->demographics"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": true,
  "webz_reporter": false,
  "external_links": [
    "https://investor-research.typeform.com/to/wvg6MFri#feedback_token=MzYzMTc0OToyOGRmNWVlN2QzYzA1NjM3&company=Maccura BiotechnologyLtd&blueprintid=3631749",
    "https://www.investor-research.typeform.com/to/wvg6MFri#feedback_token=MzYzMTc0OToyOGRmNWVlN2QzYzA1NjM3&company=Maccura BiotechnologyLtd&blueprintid=3631749"
  ],
  "external_images": [],
  "entities": {
    "persons": [],
    "organizations": [],
    "locations": []
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": null,
  "rating": null,
  "crawled": "2025-02-21T01:51:58.918+02:00",
  "updated": "2025-02-21T02:07:23.784+02:00"
}